Cargando…

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO trial (EudraCT 2014-003319-12), we investigate the activity of PARP inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chopra, Neha, Tovey, Holly, Pearson, Alex, Cutts, Ros, Toms, Christy, Proszek, Paula, Hubank, Michael, Dowsett, Mitch, Dodson, Andrew, Daley, Frances, Kriplani, Divya, Gevensleben, Heidi, Davies, Helen Ruth, Degasperi, Andrea, Roylance, Rebecca, Chan, Stephen, Tutt, Andrew, Skene, Anthony, Evans, Abigail, Bliss, Judith M., Nik-Zainal, Serena, Turner, Nicholas C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260192/ https://www.ncbi.nlm.nih.gov/pubmed/32471999 http://dx.doi.org/10.1038/s41467-020-16142-7

Ejemplares similares

Managing non-proportionality of hazards (PH) within TNT: a randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple negative (TN) or brca1/2 breast cancer (BC)
por: Tovey, Holly, et al.
Publicado: (2015)

UK NEQAS ICC & ISH Ki-67 Data Reveal Differences in Performance of Primary Antibody Clones
por: Parry, Suzanne, et al.
Publicado: (2021)

Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)
por: Bliss, Judith M., et al.
Publicado: (2023)

Opinion: PARP inhibitors in cancer—what do we still need to know?
por: Wicks, Andrew J., et al.
Publicado: (2022)

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
por: Turner, Nicholas C, et al.
Publicado: (2020)

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
por: Smith, Ian, et al.
Publicado: (2020)

Comparison of protein expression between formalin-fixed core-cut biopsies and surgical excision specimens using a novel multiplex approach
por: Leal, Mariana Ferreira, et al.
Publicado: (2019)

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor–Positive Breast Cancer
por: Gao, Qiong, et al.
Publicado: (2018)

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients
por: Gao, Qiong, et al.
Publicado: (2019)

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study
por: Lopez-Knowles, Elena, et al.
Publicado: (2022)

Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients
por: Dodson, Andrew, et al.
Publicado: (2018)

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas
por: López-Knowles, Elena, et al.
Publicado: (2016)

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
por: Dowsett, Mitch, et al.
Publicado: (2018)

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
por: Dodson, Andrew, et al.
Publicado: (2017)

A poetic story: lessons learnt from the world's largest breast cancer window of opportunity study
por: Bliss, Judith, et al.
Publicado: (2015)

A decade of clinical development of PARP inhibitors in perspective
por: Mateo, J, et al.
Publicado: (2019)

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers
por: Khalique, Saira, et al.
Publicado: (2018)

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
por: Bergamino, Milana A., et al.
Publicado: (2022)

Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma
por: Jones, Christine L., et al.
Publicado: (2021)

Introduction to sessions on 'Predicting personal risk for breast cancer'
por: Dowsett, Mitch
Publicado: (2008)

Optimizing the implementation of future treatment using surrogate end-points
por: Dowsett, Mitch
Publicado: (2008)

Predictive and prognostic factors
por: Dowsett, Mitch
Publicado: (2010)

The potential of new technologies/approaches. Introduction to Sessions 3 and 4
por: Dowsett, Mitch
Publicado: (2009)

New hurdles for translational research
por: Dowsett, Mitch
Publicado: (2000)

Conducting non-commercial international clinical trials: the ICR-CTSU experience
por: Fox, Lisa, et al.
Publicado: (2017)

Immunohistochemistry: A diagnostic aid in differentiating primary epithelial ovarian tumors and tumors metastatic to the ovary
por: Kriplani, Divya, et al.
Publicado: (2013)

The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin
por: Krastev, Dragomir B., et al.
Publicado: (2022)

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
por: Gellert, Pascal, et al.
Publicado: (2016)

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer
por: Dowsett, Mitch, et al.
Publicado: (2022)

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
por: Howell, Anthony, et al.
Publicado: (2004)

Deficits in plasma oestradiol measurement in studies and management of breast cancer
por: Dowsett, Mitch, et al.
Publicado: (2005)

Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
por: Alataki, Anastasia, et al.
Publicado: (2022)

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer
por: Burcombe, Russell, et al.
Publicado: (2006)

SOX11 promotes invasive growth and ductal carcinoma in situ progression
por: Oliemuller, Erik, et al.
Publicado: (2017)

Genomic profile of advanced breast cancer in circulating tumour DNA
por: Kingston, Belinda, et al.
Publicado: (2021)

Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA
por: Kingston, Belinda, et al.
Publicado: (2021)

Introduction to sessions on Personalising treatment
por: Dowsett, Mitch, et al.
Publicado: (2007)

A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant
por: Pettitt, Stephen J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s891hkm1h41occ016pajahlucd